Clinical trials: Progesterone
Breast Cancer
Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive and Estrogen Receptor/Progesterone Receptor Negative Breast Cancer to Evaluate the Efficiency and Safety of Treatment With Trastuzumab Plus (+) QL1209/Pertuzumab + Docetaxel.
This is a randomized, double-blind, multicenter trial，parallel control designed to evaluate treatment with trastuzumab + QL1209 + docetaxel compared with trastuzumab + pertuzumab + docetaxel in the participants with early-stage…
- Trial name
- NCT04629846
- Testing
- Trastuzumab, QL1209, Pertuzumab
- Where
- 2 sites in China
- Volunteers
- 517 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Breast Cancer, Metastasis
Study of Dasatinib (BMS-354825) in Patients With Advanced Estrogen/Progesterone Receptor-positive (ER+/PR+) or Her2/Neu-positive (Her2/Neu+)Breast Cancer
This study will determine whether the investigational drug dasatinib is effective in treatment of women with progressive advanced ER+/PR+ or Her2/neu+ breast cancer
- Trial name
- NCT00371345
- Testing
- Dasatinib, Dasatinib 100 mg
- Where
- 23 sites in United States, Argentina and 5 more
- Volunteers
- 92 people
- Sponsor
- Bristol-Myers Squibb
Infertility
Comparison of DR-2011 to a Progesterone Vaginal Gel for Luteal Phase Replacement
This is a single-center, open-label, randomized, active-controlled study to compare DR-2011 to progesterone vaginal gel for luteal phase replacement.
- Trial name
- NCT00117468
- Testing
- DR-2011, Progesterone 8% Vaginal Gel
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Duramed Research
Contraception, Gynecologic Diseases
Low Dose Continuous Administration of the Progesterone Receptor Modulator VA2914
The purpose of the present study is to evaluate continuous administration of low doses of VA2914 for potential contraceptive activity and effects on the menstrual cycle and steroid hormone parameters.
- Trial name
- NCT00456924
- Testing
- VA2914
- Where
- 4 sites in Belgium, France
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- HRA Pharma
Menopause
A Safety and Efficacy Study of the Combination Estradiol and Progesterone to Treat Vasomotor Symptoms
This study will be a prospective, randomized, double-blind, placebo-controlled, parallel group, multicenter trial of postmenopausal subjects with an intact uterus.
- Trial name
- REPLENISH (NCT01942668)
- Testing
- Estradiol, Progesterone
- Where
- 119 sites in United States
- Volunteers
- 1,845 people
- Sponsor
- TherapeuticsMD
Pharmacokinetics
A Pharmacokinetic Study to Evaluate the Bioequivalence of 2 Progesterone Vaginal Rings in Postmenopausal Women
A study to assess the pharmacokinetics of 2 progesterone vaginal rings in postmenopausal women
- Trial name
- NCT02092571
- Testing
- Progesterone vaginal ring,
- Where
- United States
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Melanoma (Excluding Uveal Melanoma), Cervical Carcinoma
A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3)
This is a Phase 1, multiple dose, ascending dose escalation study to define a MTD/RD and regimen of XmAb23104, to describe safety and tolerability, to assess PK and immunogenicity, and to preliminarily assess anti-tumor activity…
- Conditions
- Melanoma (Excluding Uveal Melanoma), Cervical Carcinoma, Pancreatic Carcinoma, Breast Carcinoma That is Estrogen Receptor, Progesterone Receptor, and Her2 Negative
- Trial name
- DUET-3 (NCT03752398)
- Testing
- XmAb®23104, Yervoy® (ipilimumab)
- Where
- 18 sites in United States
- Volunteers
- 198 people
- Sponsor
- Xencor, Inc.
Estrogen Receptor Negative (ER-Negative) Breast Cancer, Progesterone Receptor Negative (PR-Negative) Breast Cancer
A Study Evaluating INIPARIB in Combination With Chemotherapy to Treat Triple Negative Breast Cancer Brain Metastasis
The purpose of the study is to investigate the response rate for triple negative breast cancer patients with brain metastasis when INIPARIB is used in combination with irinotecan.
- Conditions
- Estrogen Receptor Negative (ER-Negative) Breast Cancer, Progesterone Receptor Negative (PR-Negative) Breast Cancer, Human Epidermal Growth Factor Receptor 2 Negative (HER2-Negative) Breast Cancer, Brain Metastases
- Trial name
- NCT01173497
- Testing
- INIPARIB + irinotecan
- Where
- 13 sites in United States
- Volunteers
- 44 people
- Sponsor
- Sanofi
Infertility
A Clinical Trial to Evaluate the Efficacy and Safety of DR-2011 for In Vitro Fertilization
This is a multi-center study to evaluate the effects of DR-2011 compared to a progesterone gel in women undergoing in vitro fertilization with fresh eggs.
- Trial name
- NCT00615251
- Testing
- DR-2011, Crinone 8%
- Where
- 29 sites in United States
- Volunteers
- 1,297 people, healthy volunteers welcome
- Sponsor
- Duramed Research
Vulvovaginal Atrophy, Vasomotor Symptoms
A Phase 1, Open-Label, Parallel Group Study to Evaluate the Pharmacokinetics and Safety of DARE-HRT1 in Healthy PostMenopausal Women
An open-label study to assess the PK of estradiol, estrone and progesterone from the DARE-HRT1 intravaginal rings at two different dose strengths.
- Trial name
- NCT05418426
- Testing
- IVR Dose 1, IVR Dose 2, Oral Reference
- Where
- 2 sites in Australia
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Daré Bioscience, Inc.
Premature Birth
Vaginal Progesterone in Twins With Short Cervix
A Multicenter, Double-Blind, Placebo-Controlled Randomized Clinical Trial of Vaginal Progesterone to Prevent Early Preterm Birth In Twin Pregnancy with Short Cervix.
- Trial name
- NCT01812239
- Testing
- Vaginal Progesterone gel., fetal fibronectin swab.
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Obstetrix Medical Group
Preterm Birth
Efficacy Study of a Cervical Pessary Containing Progesterone for the Prevention of Preterm Delivery
Assess the efficacy of 2 Cervical Pessaries containing 6.3 g and 7.7 g micronized progesterone for the prevention of preterm delivery, established through spontaneous birth before gestation weeks 32 (31 weeks and 6 days) and 34…
- Trial name
- PCP002 (NCT02225353)
- Testing
- Progesterone Cervical Pessary 6.3 g, Progesterone 200 mg vaginal capsules, Progesterone Cervical Pessary 7.7 g
- Where
- 4 sites in Chile
- Volunteers
- 271 people, healthy volunteers welcome
- Sponsor
- Grünenthal GmbH
Breast Neoplasms
Phase II Metastatic ER+/PgR+ Nolvadex +/- Iressa Study
This study is being carried out to see if ZD1839 is effective in treating metastatic breast cancer in combination with Nolvadex, and if so, how it compares with Nolvadex alone.
- Trial name
- NCT00229697
- Testing
- Gefitinib, Tamoxifen
- Where
- 55 sites in United States, Argentina and 10 more
- Volunteers
- 317 people
- Sponsor
- AstraZeneca
Pregnancy
Vaginal Progesterone to Reduce the Risk of Another Preterm Birth
This research study is being conducted at over 12 pregnancy research centers in the US. The study will compare an investigational treatment with a placebo (a treatment without medication).
- Trial name
- NCT00086177
- Testing
- 8% progesterone vaginal gel
- Where
- 45 sites in United States
- Volunteers
- 636 people, healthy volunteers welcome
- Sponsor
- Juniper Pharmaceuticals, Inc.
Breast Cancer
A Rollover Protocol of Elacestrant, in Combination With Onapristone, for Patients With ER+, PR+, HER2- Advanced or Metastatic Breast Cancer
This is a rollover study for patients enrolled in the discontinued ELONA clinical trial (ONA-XR-103) with the primary objective to characterize the safety of elacestrant in combination with onapristone either alone or in…
- Trial name
- NCT06938711
- Testing
- Elacestrant, Onapristone
- Where
- United States
- Sponsor
- Context Therapeutics Inc.
Contraception, Female Contraception
A Comparative Pharmacokinetic Study of ORTHO EVRA (a Transdermal Contraceptive Patch) and CILEST (an Oral Contraceptive) in Healthy Female Volunteers
The objective of this study is to compare the levels of the hormones norelgestromin, norgestrel, and ethinyl estradiol in the bloodstream of healthy female volunteers administered ORTHO EVRA® (a transdermal contraceptive patch)…
- Trial name
- NCT00254865
- Testing
- EVRA® transdermal contraceptive patch containing 6 mg of norelgestromin and 0.75 mg of ethinyl estradiol (versus CILEST® tablets).
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Secondary Amenorrhea
Safety and Efficacy of PROMETRIUM® Capsules in Induction of Secretory Conversion
To evaluate the efficacy and safety of 300 mg and 400 mg doses of PROMETRIUM® capsules in women of reproductive age with secondary amenorrhea
- Trial name
- NCT00160199
- Testing
- PROMETRIUM® 300 mg, PROMETRIUM® 400 mg
- Where
- 42 sites in United States
- Volunteers
- 240 people
- Sponsor
- Solvay Pharmaceuticals
Luteal Phase Insuffiency, Progesterone Delivery
First in Human Safety and Ease of Use Assessment of 400mg Progesterone Callavid in Women With Luteal Phase Insufficiency
The aim of this clinical trial is to assess safety of a new vaginal 400mg progesterone drug-device combination product in a first in human trial.
- Trial name
- FREEDOM (NCT07136922)
- Testing
- 400mg progesterone Callavid - 2hr wear, Cyclogest 400 mg, 400mg progesterone Callavid - 3hr wear
- Where
- United Kingdom
- Volunteers
- 20 people
- Sponsor
- Calla Lily Clinical Care Ltd
Endometrial Cancer
An Endometrial Cancer Study for Women With Recurrent or Persistent Endometrial Cancer
This is an open-label, multi-center, single-arm, two-period Phase 2 study. The study will investigate the efficacy of Sodium Cridanimod in conjunction with progestin therapy in a population of subjects with recurrent or…
- Trial name
- NCT03077698
- Testing
- Sodium Cridanimod, progestin therapy
- Where
- 25 sites in United States
- Volunteers
- 25 people
- Sponsor
- Xenetic Biosciences, Inc.
Breast Cancer
Study of Letrozole Plus Tipifarnib or Placebo in the Treatment of Advanced Breast Cancer
The purpose of this study is to determine if the addition of tipifarnib to standard letrozole therapy leads to a better response to treatment for your cancer in comparison to letrozole plus a placebo.
- Trial name
- NCT00050141
- Testing
- ZARNESTRA, tipifarnib, R115777
- Where
- 23 sites in United States, Belgium and 4 more
- Volunteers
- 121 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.